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Sleep and depression
Two qualitatively different brain states characterize nor-
mal human sleep: non–rapid eye movement (NREM)
and rapid eye movement (REM) sleep. NREM sleep is
further subdivided into four stages: stage 1 is the light-
est and stage 4 the deepest. Stages 3 and 4 are often
defined as δ sleep or slow-wave sleep (SWS) due to the
occurrence of slow (0.5-3.5 Hz) “delta” waves. REM
sleep (also called paradoxical sleep) alternates with
NREM throughout the night in recurrent NREM-REM
cycles of about 90 min. Sleep-wake regulation is classi-
cally viewed as resulting from the interaction of two reg-
ulating processes (homeostatic [S] and circadian [C]).
1
In this model,the propensity to sleep or be awake at any
given time is a consequence of a sleep debt (Process S)
and its interaction with signals coming from the circa-
dian clock located in the suprachiasmatic nucleus
(Process C).
In 1982, Borbely and Wirz-Justice
2 suggested that the
characteristic sleep disturbances of major depressive
patients reflect a homeostatic Process S deficiency, ie, a
failure to accumulate SWS pressure during the daytime,
leading to sleep initiation and maintenance difficulties,
and early emergence of REM sleep. Indeed, character-
istic sleep EEG changes such lengthening of sleep
latency,sleep disruption,and disturbances in REM sleep
organization have been consistently identified in depres-
sive illness.
3 Spectral analysis of NREM sleep in major
depressed patients has shown lower δ activity (power
spectra in the δ wave) in NREM sleep
4-6 and decreased
δ incidence particularly in the first non-REM period,
7
supporting the “Process S”deficiency hypothesis.Using
spectral analysis of the sleep-onset period, we have
recently brought support to this hypothesis: we found
that homeostatic sleep regulation processes are partially
maintained in primary insomniacs, but not in major
depressed patients with insomnia.
8
Sleep EEG and antidepressant response
Some studies have shown that the clinical response to
various antidepressant therapies could be predicted by
sleep electroencephalography (EEG) parameters. For
instance, the amount of REM sleep suppression
observed after the first dose of antidepressant may pre-
dict ultimate clinical response.
9,10 REM rebound follow-
ing antidepressant withdrawal was also found predictive
of antidepressant response.Kupfer et al
11 demonstrated
that the antidepressant response to two consecutive days
of pulse loading of clomipramine followed by placebo
was positively correlated with the amount of REM
rebound. Similarly, Gillin et al
9 noted that patients who
improved during treatment with amitriptyline exhibit a
clear REM sleep rebound during withdrawal, whereas
patients with no improvement show no such REM sleep
rebound. Induction of cytokine synthesis and fever has
been shown to suppress REM sleep and improve mood
in patients with major depression.
12 Finally,some studies
showed that increased REM activity (ie,more rapid eye
movements occurring during REM sleep) identify
depressive patients who do not respond to psychother-
apy and may warrant somatic treatment.
13,14
The results of some studies cast doubt on the value of
REM suppression as a predictor of antidepressant
response. For instance, data suggest that effective long-
term pharmacotherapy of recurrent major depression
with imipramine
15 or nortriptyline
16 is associated with
Copyright © 2004 LLS SAS. All rights reservedhigher REM activity than that observed in patients
relapsing while receiving these drugs.Other studies were
unable to demonstrate a consistent relationship between
REM decreases and the alleviation of depression during
treatment with antidepressants.
17-19 The REM suppres-
sant effect may play an important role in the mechanism
underlying treatment response,but is insufficient for use
in prediction.
It is also not clear whether changes in NREM sleep,
including SWS, are related to improvement in depres-
sion. Quantification of NREM sleep changes by visual
scoring of sleep EEG in terms of changes in duration or
proportion may be insufficient for detection of such a
relationship.A more accurate method may be to inves-
tigate whether clinical response is related to drug-
induced modification of sleep microstructure. For
instance,the number of transient polysomnographic acti-
vations suggestive of an awake state (ie, microarousal)
occurring during stage 2 observed after the first doses of
doxepine was found to be positively associated with anti-
depressant response.
20 Other studies have shown that
methods involving spectral analysis of NREM sleep are
useful for prediction of clinical responsiveness to anti-
depressants.
Power spectral analysis and 
antidepressant response
A classical way to describe an EEG signal is in terms of
frequency of the common EEG bands.One of the most
useful methods to decompose EEG signals into fre-
quency components is Fourrier analysis, and the fast
Fourrier transform (FFT) algorithm has been exten-
sively used in EEG analysis.In FFT spectral analysis,sig-
nal intensity is calculated per bandwidth and a power
spectral density can be obtained for each frequency
band of interest.
Predicting clinical response through the sleep EEG
spectral analysis of depressed patients has received lit-
tle interest to date.The few studies on the topic showed
that high pretreatment δ activity
5,21 and redistribution of
δ activity to the earlier part of the night may predict ulti-
mate clinical response.
22 For instance, we have shown a
clear relationship between baseline sleep EEG spectral
density values and clinical response (Figure 1).Another
study has shown that different forms of δ activity can
distinguish between acute depression and the risk of
recurrence in previously recovered patients.On the basis
of fundamental studies
23 showing that the δ bandwidth
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Figure 1. Electroencephalography (EEG) spectral analysis baseline parameters in responders (gray) and nonrespon-
ders (blue).
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(thought to be generated in thalamic nuclei) also con-
tains slow oscillations (0.5-1 Hz) originating in the cor-
tex,Buysse et al
24 demonstrated that high δ activity (2-3
Hz) was more related to the acute depressive state,while
the lower frequencies (0.5-1 Hz) were linked to risk of
recurrence. Other research efforts focused on the sig-
nificance of α frequency during REM sleep. In a topo-
graphic study, we found that REM α power spectra are
reduced after antidepressant administration in healthy
volunteers  (Figure 2),
25 a finding that needs to be
extended to depressed patients in order to assess its
potential predictive value.
Another promising direction for future research is the
study of change in dynamic relationships,or coherence,
between frequency ranges.
26 Coherence evaluates the
strength of covariation between two frequency rhythms:
if two frequencies have high coherence, they are likely
to be controlled by the same or similar timing mecha-
nism.In this context,Armitage et al
27 reported that β and
δ rhythms were less coherent in depressive patients than
in healthy controls, and Röschke et al
28 suggested that
4 weeks’ administration of paroxetine in healthy volun-
teers significantly increased coherence between β and δ
frequencies.
Figure 2. Effects of fluoxetine 20 mg on topographical alpha activity distribution during rapid eye movement
(REM) sleep. F4C4, frontocentral derivation; C4P4, centroparietal derivation; P4O2, parieto-occipital
derivation.
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Conclusion
Clinical research on the influence of antidepressant drugs on sleep microarchitecture will
become increasingly important for interpreting the effects of antidepressants on sleep physiolo-
gy and for the development of new antidepressant therapies. In this regard, spectral EEG sleep
profiles represent a promising tool for the prediction of clinical response to antidepressant
treatment.81
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